Garima Shrivastava

Journal article Journal of Human Immunity · May 1, 2026 Deficiency of adenosine deaminase 2 (DADA2) was identified in 2014 as a novel inborn error of immunity caused by biallelic pathogenic variants in ADA2. DADA2 patients express two predominant clinical phenotypes: (1) autoinflammatory vasculitis/vasc ... Full text Cite

An updated management approach of Pompe disease patients with high-sustained anti-rhGAA IgG antibody titers: experience with bortezomib-based immunomodulation.

Journal article Front Immunol · 2024 INTRODUCTION: High sustained anti-rhGAA antibody titers (HSAT; ≥12,800) are directly linked to reduced efficacy of enzyme replacement therapy (ERT) and subsequent clinical deterioration in infantile-onset Pompe disease (IOPD). We have previously demonstrat ... Full text Link to item Cite

Targeting LIN28: a new hope in prostate cancer theranostics.

Journal article Future oncology (London, England) · October 2021 The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog ... Full text Cite

Overview of key molecular and pharmacological targets for diabetes and associated diseases.

Journal article Life sciences · August 2021 Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decre ... Full text Cite

Small interfering RNA for cancer treatment: overcoming hurdles in delivery.

Journal article Acta pharmaceutica Sinica. B · November 2020 In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to de ... Full text Cite

Nucleic Acid Aptamers as a Potential Nucleus Targeted Drug Delivery System.

Journal article Current drug delivery · January 2020 BackgroundNucleus targeted drug delivery provides several opportunities for the treatment of fatal diseases such as cancer. However, the complex nucleocytoplasmic barriers pose significant challenges for delivering a drug directly and efficiently ... Full text Cite

Dynamics of Prolyl Hydroxylases Levels During Disease Progression in Experimental Colitis.

Journal article Inflammation · December 2019 Hypoxia inducible factor (HIF)-prolyl hydroxylase (PHD) inhibitors are shown to be protective in several models of inflammatory bowel disease (IBD). However, these non-selective inhibitors are known to inhibit all the three isoforms of PHD, i.e. PHD-1, PHD ... Full text Cite

Identification of a Nucleoporin358-Specific RNA Aptamer for Use as a Nucleus-Targeting Liposomal Delivery System.

Journal article Nucleic acid therapeutics · October 2016 An active targeting drug delivery system that targets the nucleus could solve the problem of the treatment of genetic disorders through gene delivery, but it has met with limited success. The purpose of this study was to establish an RNA aptamer-modified n ... Full text Cite

The screening of RNA aptamers specific for carbonic anhydrase I using the Systematic Evolution of Ligands by an Exponential Enrichment Method (SELEX).

Journal article Nucleosides, nucleotides & nucleic acids · January 2014 Carbonic anhydrases (CA) or carbonate dehydratases are a family of enzymes that catalyze the rapid interconversion of carbon dioxide and water to bicarbonate. CA I is the most abundant protein in the cytosol and has been reported to the partially associate ... Full text Cite